STORY FROM: Drugs & Medical Devices

FDA Adds 'Increased Risk of Death' Boxed Warning to Gout Drug Uloric

WASHINGTON, D.C. — The Food and Drug Administration has ordered the makers of Uloric (febuxostat) to add a boxed warning concerning an increased risk of death with the prescription gout drug as compared to a different medicine, allopurinol.

In a Feb. 21 alert, the agency explained that its conclusion is based upon its in-depth review of results from a safety clinical trial conducted by the drug’s manufacturer, Takeda Pharmaceutical, which found an increased risk of heart-related death and death from all causes with Uloric.

“Health care professionals should reserve Uloric for use only in patients who have failed or do ...



Registered User Login

Username

Password

True